Erratum to the effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

In the article entitled “The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension (1), there are some errors. In Table 2, the data about in hospital mortality should be deleted, because the correct data about in hospital mortality have been showed in Table 6. The Table 2 should be replaced by the following table.

Table 2. Comparison of demographic and clinical characteristics of patients with COVID-19 between Group A (including RAS blockers treatment) and Group B (non-RAS blockers treatment).

	Group A (n=20)	Group B (n=30)	P value
Age (yrs, mean ± SD)	52.65±13.12	67.77±12.84	0.000
Age ≥65, n (%)	4 (20)	19 (63.33)	0.003
Male gender, n (%)	10 (50)	17 (56.67)	0.643
Underlying disease, n (%)			0.140
Diabetes mellitus	0 (0)	4 (13.33)
CAD	0 (0)	1 (3.33)
COPD	1 (5)	0 (0)
Anemia	1 (5)	0 (0)
Time since disease onset (days)	13.25±2.17	15.17±4.05	0.059
Highest temperature (oC)	38.54±0.84	38.13±1.01	0.140
Symptoms, n (%)
Fever	19 (95)	28 (93.33)	1.000
Cough	13 (65)	20 (66.67)	0.903
Expectoration	2 (10)	8 (26.67)	0.149
Dyspnea	3 (15)	9 (30)	0.371
Diarrhoea	3 (15)	3 (10)	0.672
Muscle ache	2 (10)	4 (13.33)	1.000
Fatigue	9 (45)	9 (30)	0.279
Anorexia	4 (20)	5 (16.67)	1.000
Vital signs
Heart rate (bpm)	88.65±18.25	85.1±14.22	0.444
Respiratory rate (breaths per minute)	20.2±3.89	20.87±4.48	0.590
Systolic BP (mmHg)	124.9±17.24	128.5±19.55	0.507
Diastolic BP (mmHg)	77.25±12.48	77.83±12.3	0.871
Clinical severity, n (%)			0.227
Mild-moderate	7 (35)	6 (20)
Severe	12 (60)	18 (60)
Critically ill	1 (5)	6 (20)

Data are expressed as mean ± SD or number (%); P values denoted the comparison between A and B subgroups. COVID-19, coronavirus disease 2019; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; BP, blood pressure.

We regret the errors.